Wealth Enhancement Advisory Services’s Monte Rosa Therapeutics GLUE Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$253K	Sell	24,526 -1,395	-5%	-$23.9K	﹤0.01%	3519
2026 Q2	$597K	Sell	25,921 -1,156	-4%	-$21.8K	﹤0.01%	2519
2026 Q1	$463K	Buy	27,077 +4,788	+21%	+$91.6K	﹤0.01%	2379
2025 Q4	$357K	Buy	22,289 +3,746	+20%	+$50.5K	﹤0.01%	2768
2025 Q3	$137K	Sell	18,543 -1,464	-7%	-$7.75K	﹤0.01%	3259
2025 Q2	$97.4K	Buy	+20,007	New	+$89.2K	﹤0.01%	3140

Other funds holding GLUE

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Wealth Enhancement Advisory Services's GLUE Position: Q3 2026 in Review

Wealth Enhancement Advisory Services reduced its Monte Rosa Therapeutics (GLUE) stake by 5.4% in Q3 2026, selling an estimated $23.9K and leaving 24,526 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #3519.

Wealth Enhancement Advisory Services first reported a position in GLUE in Q2 2025 and has held it in 6 quarters since. The position peaked at $597K in Q2 2026. 71 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

Wealth Enhancement Advisory Services held 24,526 shares of Monte Rosa Therapeutics worth $253K as of Q3 2026.
Wealth Enhancement Advisory Services sold 1,395 Monte Rosa Therapeutics shares in Q3 2026, an estimated $23.9K.
Monte Rosa Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3519 holding.
Wealth Enhancement Advisory Services first reported a position in Monte Rosa Therapeutics in Q2 2025 and has held it in 6 quarters since.
Wealth Enhancement Advisory Services's Monte Rosa Therapeutics position peaked at $597K in Q2 2026.
71 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.